RESUMO
The present investigation deals with the evaluation for the first time of the in vitro antimicrobial and α-glucosidaseinhibitory potential of a series of 15 enantiopure cycloalkylglycines using agar well diffusion and spectrophotometricmethods, respectively. The obtained results were compared to the positive controls. The antimicrobial results revealedthat all compounds exerted strongly inhibitory activity, especially against Gram-positive bacterial strains with the mostpotent activity was ascribed to α-γ-hydroxy-α-amino acids 11–14 [minimum inhibitory concentration (MIC) = 1.58–12.50 mg/ml, minimum bactericidal concentration (MBC) = 3.17–100 mg/ml, and minimum fungicidal concentration(MFC) = 6.25–50 mg/ml], followed by both isoxazolidine 5–9 (MIC = 1.58–12.50 mg/ml, MBC = 6.25–100 mg/ml,and MFC = 25–100 mg/ml) and isoxazine 10 (MIC = 3.17–12.50 mg/ml, MBC = 3.17–50 mg/ml, and MFC = 25–50mg/ml) compounds, and slightly inhibitory effect with α-amino-γ-lactones series 1–4 (MIC = 3.17–25 mg/ml, MBC =6.25–100 mg/ml, and MFC = 25–100 mg/ml). All the derivatives exhibited a potent α-glucosidase inhibitory activitywith compound 10 (IC50 = 30.1 ± 0.6 μM) was found to be the most active. The druglikeness and pharmacokineticprofiles have been also predicted. The in silico results indicate that all derivatives showed a resemblance with severalparameters of the antimicrobial standards, especially in terms of molecular property, bioavailability, lipophilicity,medicinal chemistry, and enzymatic inhibitory effects as well as they agree with the different drug discovery rules suchas Lipinski (Pfizer), Ghose (Amgen), Veber (GlaxoSmithKline), Egan (Pharmacia), and Muegge (Bayer) displaying ahigher druglikeness behavior.